Output details

Prevention of strain-related osteopenia in aseptic loosening of hip prostheses using perioperative bisphosphonate.

This study showed the significant effect that bisphosphonate treatment had on reducing the amount of bone loss seen adjacent to femoral components. In humans this bone loss contributes to aseptic loosening and failure of the implant costing the NHS £59 million a year. Bisphosphonates are currently used to treat osteoporosis and patients with bone metastases and this study showed the significant effect that bisphosphonate treatment had on reducing bone loss following hip surgery in an ovine model. This potentially has impact on treating patients with hip replacements (70,000 patients per year, UK) where administration of bisphosphonates may reduce revisions.